Ryvu Therapeutics is a clinical-stage biopharmaceutical company based in Krakow, Poland. It discovers and develops small-molecule medicines aimed at cancer, with programmes focused on immuno-oncology and targeted therapies that act on specific molecular pathways inside tumour cells and the immune system. Its work spans early drug discovery through clinical testing, and it partners with academic groups and pharmaceutical companies to advance its candidate compounds. The company serves the oncology treatment field, where new medicines are developed for patients with difficult-to-treat cancers.
Ryvu Therapeutics SA trades under the code RVU on the Warsaw Stock Exchange in Poland, with its price quoted in Polish zloty (PLN). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #382 of 580 on the Warsaw Stock Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Poland yet.
TrendWeak
27/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-6.0%
From 52-week high-37.8%
MomentumWeak
41/100
Lagging most stocks on this exchange.
See the numbers →
3-month return23.8%
6-month return-21.0%
12-month, skipping last month-36.2%
Stability (higher is calmer)Weak
30/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)47.0%
Worst drawdown, 1 year (smaller is calmer)-54.0%
LiquidityStrong
83/100
Trades actively.
See the numbers →
Avg daily value traded0.58M PLN
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Poland when fundamentals data for this market is added. All Poland stocks.
52-wk range 13.64 – 31.90Daily closes, split-adjusted
Signals
50-day average17.09
200-day average19.79
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.72
Technical summary
Daily
Bullish
10 bullish · 1 neutral · 5 bearish
Weekly
Neutral
5 bullish · 1 neutral · 6 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 10
17.74
Bullish
EMA 10
17.77
Bullish
SMA 20
16.95
Bullish
EMA 20
17.31
Bullish
SMA 50
17.09
Bullish
EMA 50
16.95
Bullish
SMA 100
16.12
Bullish
EMA 100
17.42
Bullish
SMA 200
19.79
Bearish
EMA 200
19.62
Bearish
Oscillators (daily)
RSI (14)
67.59
Neutral
MACD (12, 26)
0.47
Bullish
Momentum (12)
12.73
Bullish
Stochastic %K (14)
89.66
Bearish
Williams %R (14)
-10.34
Bearish
CCI (20)
132.8
Bearish
Pivot points (classic, last session)
S3
17.25
S2
17.63
S1
18.11
Pivot
18.49
R1
18.97
R2
19.35
R3
19.83
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in PLN. Educational only, not financial advice.
